^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCL19 overexpression

    i
    Other names: CCL19, CKb11, ELC, exodus-3, MIP-3b, SCYA19, Chemokine (C-C motif) ligand 19
    Entrez ID:
    6363
    Related biomarkers:
    Expression
    Others
    1year
    Assessment of baseline CCL19+ dendritic cell infiltration for predicting responses to immunotherapy in lung adenocarcinoma patients (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
    The baseline CCL19+ DC infiltration level in lung adenocarcinoma microenvironment is positively correlated with immunotherapy efficacy and CTL infiltration and can thus predict the response to immunotherapy.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CCL19 (C-C Motif Chemokine Ligand 19) • GZMB (Granzyme B) • PRF1 (Perforin 1)
    |
    CD8 expression • CCL19 overexpression
    4years
    Follicular Lymphoma Microenvironment Signatures Define Patients Subsets Obtaining Long Term Clinical Benefit after Single-Agent First-Line Anti-CD20 Immunotherapy (ASH 2021)
    The results here reported indicate that pts with a favorable immune signature could derive maximal benefit from a first-line chemo-free treatment approach with single agent Rituximab, achieving and maintaining complete remission in the long term, irrespective of the tumor burden and other clinical variables. Thus, profiling of FL microenvironment with T-GEP could provide a useful tool for selecting patients who may be suitable for a chemo-free upfront treatment with anti CD20 immunotherapy.
    Clinical • IO biomarker
    |
    CCL19 (C-C Motif Chemokine Ligand 19) • CCL2 (Chemokine (C-C motif) ligand 2) • TNFRSF4 (TNF Receptor Superfamily Member 4) • IL17A (Interleukin 17A) • CCL22 (C-C Motif Chemokine Ligand 22) • IL17RB (Interleukin 17 Receptor B)
    |
    CD20 expression • CD20 overexpression • CCL19 overexpression • 6-gene signature
    |
    Rituxan (rituximab)